Smoking cessation is essential, and pulmonary rehabilitation may improve quality of life and functional capacity for patients with any ILD. Pharmacologic options include single-agent or combination corticosteroid therapy and immunomodulating or antifibrotic agents (azathioprine, cyclophosphamide, colchicine, D-penicillamine). Overall, these therapies have shown marginal to no benefit in cases
of idiopathic pulmonary fibrosis, whereas patients with other ILDs may have a better response (Davies et al., 2003). A meta-analysis of 390 patients with pulmonary fibrosis did find that interferon gamma-1b therapy significantly reduced mortality (Bajwa et al., 2005). Causes of death identified for pulmonary fibrosis in one study included respiratory failure (39%), cardiovascular disease (27%), lung cancer (10%), pulmonary infection or emboli (6%) (Panos, 1990).
Unilateral lung transplantation may enhance survival and functioning in patients with advanced interstitial fibrosis with chronic respiratory failure, whereas pulmonary fibro-sis with pulmonary hypertension may require bilateral lung transplantation (Alalawi et al., 2005). One-year survival after lung transplantation is 75%, with 44% of patients surviving 5 years or longer (Trulock, 2001).
Was this article helpful?
How To Maintain The Stop Smoking Pledge From Your New Year’s Resolution. Get All The Support And Guidance You Need To Be A Success At Quitting Smoking. This Book Is One Of The Most Valuable Resources In The World When It Comes To How To Maintain The Stop Smoking Pledge From Your New Year’s Resolution.